Hypermetabolic abdominal and cervical lymph nodes mimicking Hodgkin lymphoma relapse on FDG PET/CT after adenovirus-vectored COVID-19 vaccine

Landete, Elena; Gómez-Fernández, Isabel; Marín, Isabel González-Gascón y; Durán-Barquero, Carmen; Churruca, Juan; Infante, María Stefania; Muñoz‐Novas, Carolina; Foncillas, María Ángeles; Marín, Karen; Ramos-de-Ascanio, Victoria; Farto, J.C. Alonso; Hernández‐Rivas, José‐Ángel

doi:10.1080/21645515.2021.2008215

Cited by 11 publications

(15 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To the best of our knowledge, this is the first review of malignant lymphoma diagnosed shortly after COVID-19 vaccination. Previous reports showed a progression or pseudo-progression of the disease in patients with a pre-existing lymphoma [ 16 , 17 , 18 , 19 , 20 ]. On the other hand, it must be emphasized that spontaneous tumor regression after COVID-19 vaccination was reported in a patient with metastatic myoepithelial carcinoma of the left parotid [ 21 ] and in a patient with cutaneous anaplastic large-cell lymphoma [ 22 ].…”

Section: Discussionmentioning

confidence: 99%

Non-Hodgkin Lymphoma Developed Shortly after mRNA COVID-19 Vaccination: Report of a Case and Review of the Literature

et al. 2023

View full text Add to dashboard Cite

We report on a 66-year-old man who presented with a right axillary lymphadenopathy approximately 10 days after receiving the third dose of the BNT162b2 vaccine. The lymphadenopathy gradually enlarged, and physical examination and ultrasound (US) revealed one right axillary 6.99 cm and one right supraclavicular 2.36 cm lymphadenopathy. Histologic examination of the right axillary nodule revealed anaplastic large-cell lymphoma that was ALK negative and CD30 positive. A total body computerized tomography (CT) scan, positron emission tomography (PET) and bone-marrow biopsy showed a stage-II non-Hodgkin lymphoma (NHL). The patient was treated with chemotherapy and a scheme of Brentuximab Vedotin, Cyclophosphamide, Doxorubicin and Prednisone (BV-CHP) for six cycles and is now well and in complete remission. The revision of the literature revealed eight additional cases of NHL developed shortly after COVID-vaccination. There were four cases of diffuse large-B-cell lymphoma (DLBCL) (one in a patient who was a heart transplant recipient and developed an Epstein–Bar-virus-positive DLBCL), one case of extranodal NK/T-cell lymphoma, one patient with subcutaneous panniculitis-like T-cell lymphoma, one case of marginal zone B-cell lymphoma and one primary cutaneous anaplastic large-cell lymphoma (PC-ALCL). In five cases, the lymphoma developed after BNT162b2 mRNA vaccination, including one case after ChAdOx1 nCOV-19, one case after the adenovirus type 26 (Ad26) vaccine and one after mRNA-1273/Spikevax (ModernaTX). We are aware that the link between COVID-19 vaccination and lymphoma most likely is a chance phenomenon, and that COVID-19 vaccines represent very efficient products for many people around the world. However, we believe that clinical events, even if only temporally associated with novel treatments or novel vaccines, should be reported for the benefit of the patients and the scientific community.

show abstract

Section: Discussionmentioning

confidence: 99%

Non-Hodgkin Lymphoma Developed Shortly after mRNA COVID-19 Vaccination: Report of a Case and Review of the Literature

et al. 2023

View full text Add to dashboard Cite

show abstract

“…As different studies show, this condition can be challenging when occurring in oncological patients: it is hard to define whether the lymphnodes uptake is due to a cancer recurrence or not [ 10 , 11 ], particularly when considering fluorine-18 choline (F-FCH) PET-CT increased uptake.…”

Section: Discussionmentioning

confidence: 99%

COVID-19 vaccination simulating lymph node progression in a patient with prostate cancer

Andresciani

Ricci

Grasso

et al. 2022

Radiology Case Reports

View full text Add to dashboard Cite

“…Only a single case reported the same AE for a female with history of Classic Hodgkin Lymphoma who underwent follow-up [18F] FDG PET-CT, after administration of adenovirus-vectored Oxford-AstraZeneca COVID-19 vaccine. [ 21 ] We hypothesize that the reason for more events that reported after the administration of both Pfizer-BioNTech and Moderna vaccines was the use of these vaccines was more common than that of other vaccines.…”

Section: Discussionmentioning

confidence: 99%

Metabolic Activity Assessment by 18F-Fluorodeoxyglucose Positron Emission Tomography in Patients after COVID-19 Vaccination

et al. 2022

View full text Add to dashboard Cite

In the following report, we describe 11 patients with various diagnoses and different treatment statuses (newly diagnosed, receiving treatment, or follow-up) of oncological diseases (breast, lymphoma, melanoma, and head and neck cancers). The patients underwent PET-CT for disease staging or follow-up and it was noted that all patients had areas of hypermetabolic uptake in the axillary lymph-nodes of the ipsilateral upper extremity where the Pfizer-BioNTech coronavirus (COVID-19) vaccine was administered. Following further investigations, including an ultrasound (US), biopsies and an examination of medical records, it was concluded that these findings were the result of the vaccination and not a progression of pre-existing disease.

show abstract

Hypermetabolic abdominal and cervical lymph nodes mimicking Hodgkin lymphoma relapse on FDG PET/CT after adenovirus-vectored COVID-19 vaccine

Cited by 11 publications

References 17 publications

Non-Hodgkin Lymphoma Developed Shortly after mRNA COVID-19 Vaccination: Report of a Case and Review of the Literature

Non-Hodgkin Lymphoma Developed Shortly after mRNA COVID-19 Vaccination: Report of a Case and Review of the Literature

COVID-19 vaccination simulating lymph node progression in a patient with prostate cancer

Metabolic Activity Assessment by 18F-Fluorodeoxyglucose Positron Emission Tomography in Patients after COVID-19 Vaccination

Contact Info

Product

Resources

About